Dengue viruses threaten over 3.5 billion people worldwide and cause an estimated 50 - 100 million cases of dengue fever every year. Due to global urbanization and increased travel, dengue continues to spread worldwide. Dengue fever is caused by infection with one of four different RNA viruses: DEN-1, DEN-2, DEN-3 or DEN-4. To be safe and effective, a dengue vaccine must be capable of neutralizing all four of the dengue viruses. Inviragen ™s dengue vaccine technology, developed by researchers at the CDC, is based on a safe virus backbone that generates long-lasting anti-dengue immune responses. Using this technology, Inviragen has developed a four-way vaccine to protect against all four of the different viruses that cause dengue fever. Human clinical testing of the Inviragen vaccine is expected to begin in the coming months. If Inviragen ™s dengue vaccine is proven to be safe and effective in human clinical trials, it may be used to protect children and adults who live in dengue-endemic countries and to protect travelers to those regions from this debilitating and dangerous disease.

www.inviragen